Wilson disease: Histopathological correlations with treatment on follow-up liver biopsies

Table 1 Baseline characteristics of patients who showed progression of the histologic score (progressors) vs those who showed overall improvement or no progression in histology (non-progressors)

	Progressors	Non-progressors
Age at diagnosis (mean ± SD) (yr)	18.0 ± 8.8	16.6 ± 9.8
Phenotype	All hepatic phenotype	4 with hepatic phenotype; 2 with mixed hepatic and neurological phenotype
AST U/L (baseline) (normal range 15-43)	60.0 ± 56.8 (range 18-44) (6)	64.6 ± 51.3 (range 15-129) (6)
AST U/L (time of 2nd biopsy)	45.1 ± 48.2 (range 20-143) (6)	25.5 ± 9.7 (range 13-39) (6)
AST U/L (time of 3rd biopsy)	27.3 ± 10.2 (range 13-44) (6)	28.7 ± 10.8 (range 15-41) (3)
AST U/L (time of 4th biopsy)	24 and 28 (2)
ALT U/L (baseline) (normal range 6-43)	83.5 ± 40.2 (range 45-137) (6)	84.5 ± 60.7 (range 15-164) (6)
ALT U/L (time of 2nd biopsy)	48.5 ± 21.8 (range 24-80) (6)	26.1 ± 12.3 (range 10-46) (6)
ALT U/L (time of 3rd biopsy)	42.0 ± 17.2 (22 and 68) (2)	32.7 ± 17.2 (range 8-48) (3)
ALT U/L (time of 4th biopsy)	47.0 ± 7.0 (42 and 52) (2)
24 h urinary Cu μg/24 h (baseline)	679.7 ± 504.0 (6)	1245.0 ± 1649.0 (6)
Hepatic Cu mg/g dry liver (baseline)	534.4 ± 298.7 (6)	455.0 ± 245.3 (6)
Type of treatment	2 = penicillamine; 4 = zinc	3 = penicillamine; 3 = zinc
	One patient switched to penicillamine during follow up	No change of treatment during follow up

The numbers in brackets represent the number of patients included in the analysis.